COR 101
Alternative Names: COR-101; STE90-C11Latest Information Update: 15 Jul 2021
At a glance
- Originator Corat Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 08 Jul 2021 CORAT Therapeutics and Dermapharm Holding signs agreement for development of COR 101
- 25 Apr 2021 Phase-I/II clinical trials in COVID-2019 infections in Germany (IV) (NCT04674566)
- 16 Mar 2021 The central ethics committee recommends approval to conduct the clinical phase Ib/II trial of COR 101 for COVID-2019 infections